134 related articles for article (PubMed ID: 17896322)
1. Development of an in vivo rat screen model to predict pharmacokinetic interactions of CYP3A4 substrates.
Mandlekar SV; Rose AV; Cornelius G; Sleczka B; Caporuscio C; Wang J; Marathe PH
Xenobiotica; 2007 Sep; 37(9):923-42. PubMed ID: 17896322
[TBL] [Abstract][Full Text] [Related]
2. Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats.
Kanazu T; Yamaguchi Y; Okamura N; Baba T; Koike M
Xenobiotica; 2004 May; 34(5):403-13. PubMed ID: 15370957
[TBL] [Abstract][Full Text] [Related]
3. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
Ghosal A; Satoh H; Thomas PE; Bush E; Moore D
Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of continuous ingestion of Schisandrin A on CYP3A in the rat.
Li WL; Xin HW; Su MW
Basic Clin Pharmacol Toxicol; 2012 Feb; 110(2):187-92. PubMed ID: 21895978
[TBL] [Abstract][Full Text] [Related]
5. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
Granvil CP; Yu AM; Elizondo G; Akiyama TE; Cheung C; Feigenbaum L; Krausz KW; Gonzalez FJ
Drug Metab Dispos; 2003 May; 31(5):548-58. PubMed ID: 12695342
[TBL] [Abstract][Full Text] [Related]
6. CYP3A4-based drug-drug interaction: CYP3A4 substrates' pharmacokinetic properties and ketoconazole dose regimen effect.
Boulenc X; Nicolas O; Hermabessière S; Zobouyan I; Martin V; Donazzolo Y; Ollier C
Eur J Drug Metab Pharmacokinet; 2016 Feb; 41(1):45-54. PubMed ID: 25374256
[TBL] [Abstract][Full Text] [Related]
7. In vivo effect of Schisandrin B on cytochrome P450 enzyme activity.
Li WL; Xin HW; Yu AR; Wu XC
Phytomedicine; 2013 Jun; 20(8-9):760-5. PubMed ID: 23523258
[TBL] [Abstract][Full Text] [Related]
8. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
9. Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model.
Rioux N; Bellavance E; Bourg S; Garneau M; Ribadeneira MD; Duan J
Biopharm Drug Dispos; 2013 Oct; 34(7):396-401. PubMed ID: 23873286
[TBL] [Abstract][Full Text] [Related]
10. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.
Polasek TM; Miners JO
Eur J Clin Pharmacol; 2006 Mar; 62(3):203-8. PubMed ID: 16416302
[TBL] [Abstract][Full Text] [Related]
11. Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey.
Ward KW; Stelman GJ; Morgan JA; Zeigler KS; Azzarano LM; Kehler JR; McSurdy-Freed JE; Proksch JW; Smith BR
Drug Metab Dispos; 2004 Feb; 32(2):172-7. PubMed ID: 14744938
[TBL] [Abstract][Full Text] [Related]
12. Allosteric activation of midazolam CYP3A5 hydroxylase activity by icotinib - Enhancement by ketoconazole.
Zhuang X; Zhang T; Yue S; Wang J; Luo H; Zhang Y; Li Z; Che J; Yang H; Li H; Zhu M; Lu C
Biochem Pharmacol; 2016 Dec; 121():67-77. PubMed ID: 27666601
[TBL] [Abstract][Full Text] [Related]
13. In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat.
Kotegawa T; Laurijssens BE; Von Moltke LL; Cotreau MM; Perloff MD; Venkatakrishnan K; Warrington JS; Granda BW; Harmatz JS; Greenblatt DJ
J Pharmacol Exp Ther; 2002 Sep; 302(3):1228-37. PubMed ID: 12183684
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone.
Lam YW; Alfaro CL; Ereshefsky L; Miller M
J Clin Pharmacol; 2003 Nov; 43(11):1274-82. PubMed ID: 14551182
[TBL] [Abstract][Full Text] [Related]
15. A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib.
Derks M; Fowler S; Kuhlmann O
Clin Ther; 2009 Mar; 31(3):586-99. PubMed ID: 19393849
[TBL] [Abstract][Full Text] [Related]
16. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.
Ohno Y; Hisaka A; Suzuki H
Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375
[TBL] [Abstract][Full Text] [Related]
17. Species differences and substrate specificity of CYP3A heteroactivation by efavirenz.
Kosugi Y; Takahashi J
Xenobiotica; 2015 Apr; 45(4):345-52. PubMed ID: 25387130
[TBL] [Abstract][Full Text] [Related]
18. Current cytochrome P450 phenotyping methods applied to metabolic drug-drug interaction prediction in dogs.
Mills BM; Zaya MJ; Walters RR; Feenstra KL; White JA; Gagne J; Locuson CW
Drug Metab Dispos; 2010 Mar; 38(3):396-404. PubMed ID: 20007294
[TBL] [Abstract][Full Text] [Related]
19. Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction.
Youdim KA; Zayed A; Dickins M; Phipps A; Griffiths M; Darekar A; Hyland R; Fahmi O; Hurst S; Plowchalk DR; Cook J; Guo F; Obach RS
Br J Clin Pharmacol; 2008 May; 65(5):680-92. PubMed ID: 18279465
[TBL] [Abstract][Full Text] [Related]
20. Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes.
Miyazawa M; Shindo M; Shimada T
Drug Metab Dispos; 2001 Feb; 29(2):200-5. PubMed ID: 11159812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]